Biogen pays Elan $3.25 billion to take over MS drug
DUBLIN (Reuters) - Biogen Idec is to take full ownership of blockbuster multiple sclerosis drug Tysabri after agreeing to pay Irish partner Elan $3.25...
Source: http://feeds.reuters.com/~r/reuters/healthNews/~3/brWCjhK1Kwc/us-elan-brief-idUSBRE91509420130206
No comments:
Post a Comment